Treatment of Breakthrough Cancer Pain According to European Guidelines (BEG)
Adherence to Breakthrough Cancer Pain (BTcP) European Guidelines: an Observational Prospective Study.
Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
Terminated
Low enrollment rate
Other terminated trials from Aziende Chimiche Riunite Angelini Francesco S.p.A
More terminations from Aziende Chimiche Riunite Angelini Francesco S.p.A
Listed as NCT04468490, this observational or N/A phase trial focuses on Breakthrough Cancer Pain and remains terminated or withdrawn. Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Nov 2021 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Jan 2021 — Nov 2021 [monthly]
Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aziende Chimiche Riunite Angelini Francesco S.p.A
For direct contact, visit the study record on ClinicalTrials.gov .